摘要
目的:探讨趋化因子受体CCR6在肝癌间质成纤维细胞中的表达及其临床意义。方法:免疫组化法检测99例肝癌组织CCR6表达,探讨肝癌间质中成纤维细胞CCR6表达与临床病理特征的关系,并对随访资料进行统计学分析。结果:肝癌及癌旁间质成纤维细胞中均可检测到CCR6表达,肝癌间质成纤维细胞CCR6表达水平明显高于癌旁间质(P<0.05);肝癌间质成纤维细胞CCR6表达与肿瘤大小、肿瘤数量、血管侵犯、有无卫星灶、Edmondson Steiner病理分级以及TNM分期相关(P<0.05);肿瘤间质中成纤维细胞CCR6阳性患者3年无瘤生存率(26.2%)明显低于CCR6阴性患者(52.6%,P<0.05)。结论:原发性肝癌间质成纤维细胞CCR6表达可以作为肝癌根治术后复发的一个预后指标,为原发性肝癌的治疗提供一个新的靶点。
Objective： To investigate the expression of Chemokine Receptor CCR6 expression in hepatocellular carcinoma（HCC） associated fibroblasts and its effects on relapse-free survival（RFS） after curative resection of HCC.Methods： Expression of CCR6 was immunohistochemically detected in HCC specimens from 99 patients.All statistical analysis was performed with SPSS 13.0 software to determine the effects of stromal CCR6 on clinicopathologic factors and RFS.Results： The expression of CCR6 was detected both in hepatoma carcinoma cells and cancer-associated fibroblasts.The expression level of CCR6 in cancer-associated fibroblasts was significantly higher than that in adjacent normal tissue（P〈0.05）.CCR6 expression in HCC associated fibroblasts was significantly associated with tumor size,number of tumors,vascular invasion,satellite nodules,Edmondson Steiner grade and TNM stage（P〈0.05,for all）.Moreover,CCR6 expression in HCC associated fibroblasts was significantly associated with poorer RFS,the 3-year RFS of patients with positive expression of CCR6 in HCC associated fibroblasts was significantly lower than that of those with negative expression（26.2% versus 52.6%,P=0.005）.Conclusion： CCR6 expression in HCC associated fibroblasts was closely associated with tumor progression and poorer 3-year RFS,indicating that CCR6 expression in HCC associated fibroblasts might be a predictor of relapsing phenotype and a potential target for discovering novel therapies for patients with HCC.
出处
《中国现代普通外科进展》
CAS
2011年第12期948-951,共4页
Chinese Journal of Current Advances in General Surgery
关键词
肝肿瘤
成纤维细胞
趋化因子受体
CCR6
预后
Carcinoma； hepatocellular
Cancer-associated fibroblasts
Chemokine Receptor CCR6
Prognosis
